Oral VK2735 for Weight Management in Adults With Type 2 Diabetes Mellitus Phase 3 (SUNRISE 2)

This is a registry record, not a result. A trial being listed, recruiting or completed says nothing by itself about whether the compound works or is safe.

Registry numberNCT07868939
StatusRecruiting
PhasePhase 3
SponsorViking Therapeutics, Inc.
Enrollment560 participants
DesignInterventional, Randomized, Parallel, Masking: Double
ConditionsWeight Loss
InterventionsVK2735 Oral; Placebo Comparator
StartNov 2026
Primary completionOct 2028
Study completionDec 2028
Results postedNot yet
Registry last updatedNov 16, 2026

Compounds on this site that cite this trial

What the registry says the trial is about

This study is one of two planned Phase 3 studies to support the weight management indication for VK2735 Oral in obese (BMI ≥ 30 kg/m2) or overweight (BMI ≥ 27 kg/m2) adults with Type 2 Diabetes Mellitus.

Primary outcomes

These are what the trial was designed to measure first. They are registered in advance, which is what makes a later result checkable.

Outcome measureTime frame
Percent change in body weight for participants with type 2 diabetes mellitus receiving VK2735 orally once daily68 weeks

Source: ClinicalTrials.gov (U.S. National Library of Medicine). Last checked against the registry on Nov 17, 2026. See the trial changes feed for what has changed recently.

Share thisFacebookXEmail